Image-Guided Convection-Enhanced Delivery Platform in the Treatment of Neurological Diseases

Massimo S. Fiandaca, John R. Forsayeth, Peter J Dickinson, Krystof S. Bankiewicz

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials for gene therapy in Parkinson's disease (PD). Benefits of this intracranial drug-transfer technology include a more efficient delivery of large volumes of therapeutic agent to the target region when compared with more standard delivery approaches (i.e., biopolymers, local infusion). In this article, we describe specific technical modifications we have made to the CED process to make it more effective. For example, we developed a reflux-resistant infusion cannula that allows increased infusion rates to be used. We also describe our efforts to visualize the CED process in vivo, using liposomal nanotechnology and real-time intraoperative MRI. In addition to carrying the MRI contrast agent, nanoliposomes also provide a standardized delivery vehicle for the convection of drugs to a specific brain-tissue volume. This technology provides an added level of assurance via visual confirmation of CED, allowing intraoperative alterations to the infusion if there is reflux or aberrant delivery. We propose that these specific modifications to the CED technology will improve efficacy by documenting and standardizing the treatment-volume delivery. Furthermore, we believe that this image-guided CED platform can be used in other translational neuroscience efforts, with eventual clinical application beyond neuro-oncology and PD.

Original languageEnglish (US)
Pages (from-to)123-127
Number of pages5
JournalNeurotherapeutics
Volume5
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Convection
Therapeutics
Parkinson Disease
Technology
Technology Transfer
Nanotechnology
Biopolymers
Brain
Neurosciences
Brain Neoplasms
Pharmaceutical Preparations
Genetic Therapy
Contrast Media

Keywords

  • brain neoplasm
  • CNS
  • Convection-enhanced delivery
  • gene transfer
  • infusion cannula
  • liposomes
  • MRI
  • Parkinson's disease
  • trophic factors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology

Cite this

Image-Guided Convection-Enhanced Delivery Platform in the Treatment of Neurological Diseases. / Fiandaca, Massimo S.; Forsayeth, John R.; Dickinson, Peter J; Bankiewicz, Krystof S.

In: Neurotherapeutics, Vol. 5, No. 1, 01.2008, p. 123-127.

Research output: Contribution to journalArticle

Fiandaca, Massimo S. ; Forsayeth, John R. ; Dickinson, Peter J ; Bankiewicz, Krystof S. / Image-Guided Convection-Enhanced Delivery Platform in the Treatment of Neurological Diseases. In: Neurotherapeutics. 2008 ; Vol. 5, No. 1. pp. 123-127.
@article{9b384861be864e12adb357ca35058d32,
title = "Image-Guided Convection-Enhanced Delivery Platform in the Treatment of Neurological Diseases",
abstract = "Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials for gene therapy in Parkinson's disease (PD). Benefits of this intracranial drug-transfer technology include a more efficient delivery of large volumes of therapeutic agent to the target region when compared with more standard delivery approaches (i.e., biopolymers, local infusion). In this article, we describe specific technical modifications we have made to the CED process to make it more effective. For example, we developed a reflux-resistant infusion cannula that allows increased infusion rates to be used. We also describe our efforts to visualize the CED process in vivo, using liposomal nanotechnology and real-time intraoperative MRI. In addition to carrying the MRI contrast agent, nanoliposomes also provide a standardized delivery vehicle for the convection of drugs to a specific brain-tissue volume. This technology provides an added level of assurance via visual confirmation of CED, allowing intraoperative alterations to the infusion if there is reflux or aberrant delivery. We propose that these specific modifications to the CED technology will improve efficacy by documenting and standardizing the treatment-volume delivery. Furthermore, we believe that this image-guided CED platform can be used in other translational neuroscience efforts, with eventual clinical application beyond neuro-oncology and PD.",
keywords = "brain neoplasm, CNS, Convection-enhanced delivery, gene transfer, infusion cannula, liposomes, MRI, Parkinson's disease, trophic factors",
author = "Fiandaca, {Massimo S.} and Forsayeth, {John R.} and Dickinson, {Peter J} and Bankiewicz, {Krystof S.}",
year = "2008",
month = "1",
doi = "10.1016/j.nurt.2007.10.064",
language = "English (US)",
volume = "5",
pages = "123--127",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Image-Guided Convection-Enhanced Delivery Platform in the Treatment of Neurological Diseases

AU - Fiandaca, Massimo S.

AU - Forsayeth, John R.

AU - Dickinson, Peter J

AU - Bankiewicz, Krystof S.

PY - 2008/1

Y1 - 2008/1

N2 - Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials for gene therapy in Parkinson's disease (PD). Benefits of this intracranial drug-transfer technology include a more efficient delivery of large volumes of therapeutic agent to the target region when compared with more standard delivery approaches (i.e., biopolymers, local infusion). In this article, we describe specific technical modifications we have made to the CED process to make it more effective. For example, we developed a reflux-resistant infusion cannula that allows increased infusion rates to be used. We also describe our efforts to visualize the CED process in vivo, using liposomal nanotechnology and real-time intraoperative MRI. In addition to carrying the MRI contrast agent, nanoliposomes also provide a standardized delivery vehicle for the convection of drugs to a specific brain-tissue volume. This technology provides an added level of assurance via visual confirmation of CED, allowing intraoperative alterations to the infusion if there is reflux or aberrant delivery. We propose that these specific modifications to the CED technology will improve efficacy by documenting and standardizing the treatment-volume delivery. Furthermore, we believe that this image-guided CED platform can be used in other translational neuroscience efforts, with eventual clinical application beyond neuro-oncology and PD.

AB - Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials for gene therapy in Parkinson's disease (PD). Benefits of this intracranial drug-transfer technology include a more efficient delivery of large volumes of therapeutic agent to the target region when compared with more standard delivery approaches (i.e., biopolymers, local infusion). In this article, we describe specific technical modifications we have made to the CED process to make it more effective. For example, we developed a reflux-resistant infusion cannula that allows increased infusion rates to be used. We also describe our efforts to visualize the CED process in vivo, using liposomal nanotechnology and real-time intraoperative MRI. In addition to carrying the MRI contrast agent, nanoliposomes also provide a standardized delivery vehicle for the convection of drugs to a specific brain-tissue volume. This technology provides an added level of assurance via visual confirmation of CED, allowing intraoperative alterations to the infusion if there is reflux or aberrant delivery. We propose that these specific modifications to the CED technology will improve efficacy by documenting and standardizing the treatment-volume delivery. Furthermore, we believe that this image-guided CED platform can be used in other translational neuroscience efforts, with eventual clinical application beyond neuro-oncology and PD.

KW - brain neoplasm

KW - CNS

KW - Convection-enhanced delivery

KW - gene transfer

KW - infusion cannula

KW - liposomes

KW - MRI

KW - Parkinson's disease

KW - trophic factors

UR - http://www.scopus.com/inward/record.url?scp=37349081554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349081554&partnerID=8YFLogxK

U2 - 10.1016/j.nurt.2007.10.064

DO - 10.1016/j.nurt.2007.10.064

M3 - Article

C2 - 18164491

AN - SCOPUS:37349081554

VL - 5

SP - 123

EP - 127

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 1

ER -